Serum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis

Abstract

BackgroundSerum tartrate-resistant acid phosphatase 5b (TRACP 5b) activity is a marker of osteoclast number and is elevated in breast cancer (BC) patients with extensive bone metastasis, which might in turn reflect the tumour burden. We tested the hypothesis that baseline serum TRACP 5b activity and its interval change are potential prognostic markers of survival in BC patients with bone metastasis.MethodsWe analyzed the data from previous prospective studies. A total of 100 patients with newly diagnosed bone metastasis were included. Cox proportional regression model was used to evaluate the correlation between the overall survival time (OS) and baseline serum TRACP 5b activity and its interval changes. The least significant change (LSC) of TRACP 5b was calculated from data obtained from 15 patients with early BC.ResultsEstrogen receptor status (Hazard Ratio (HR) = 0.397; p = 0.003) and visceral metastasis (HR = 0.492; p = 0.0045) were significantly correlated with OS. The OS was significantly shorter in those patients with higher baseline TRACP 5b activity based on a cut-off value to delineate the highest tertile (HR = 3.524; p < 0.0001). Further analysis demonstrated that among patients in the highest tertile, OS was significantly longer in those patients who had achieved a decrease of serum TRACP 5b activity greater than the LSC (38.59%) (p = 0.0015).ConclusionsWe found that TRACP 5b activity and its interval change after treatment bore a prognostic role in BC patients with bone metastasis and a high baseline serum TRACP 5b activity. Further prospective phase II study is necessary to confirm these results.

Prognostic significance of ACP5 expression in patients with lung adenocarcinoma

“…3 ACP5 expression has been shown to be significantly upregulated in breast and ovarian cancers and melanoma 4,5 and is a useful serum marker for extensive bone metastasis. [6][7][8][9][10] Recent studies have reported that ACP5 promotes the invasion and distal metastasis of melanoma and breast cancer cells through the modulation of focal adhesion kinase (FAK) phosphorylation. Additionally, ACP5 overexpression is indicative of the poor prognoses of human melanoma patients.…”

Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study

“…The study measured serum bone resorption markers at baseline and 6 months after treatment with Zoledronic acid, and used the level change of the markers (e.g., increase or decrease) after the treatments. Other reports had shown the value of TRACP‐5b in breast cancer and ICTP in nonsmall cell lung cancer for predicting survival, but another report could not document any prognostic value of pretreatment ICTP in patients with prostate cancer . A previous study of metastatic bone disease showed that percent changes of urine N‐terminal cross‐linking telopeptides of type I collagen (NTX) and serum ICTP were associated with disease progression in bone .…”

Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer

“…Over the past 20 years, researchers have identified more than a dozen proteins that may be considered biomarkers of bone metastasis in preclinical models of breast cancer and in human breast tumors (Table 1) [6-12]. Some of these biomarkers appear to be useful for monitoring bone metabolism in patients with various bone-related diseases, including osteoporosis, as well as monitoring patients receiving antiresorptive agents [13, 14].…”